B
0.559
-0.02 (-3.90%)
| Previous Close | 0.582 |
| Open | 0.577 |
| Volume | 11,166 |
| Avg. Volume (3M) | 856,281 |
| Market Cap | 22,994,202 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2026 |
| Diluted EPS (TTM) | -0.220 |
| Quarterly Revenue Growth (YOY) | 14.30% |
| Current Ratio (MRQ) | 2.49 |
| Operating Cash Flow (TTM) | -15.37 M |
| Levered Free Cash Flow (TTM) | -12.95 M |
| Return on Assets (TTM) | -18.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | BeyondSpring, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Relative Valuation | NA |
| Financial Health | -1.7 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.15 |
Select this tab to load the latest available analysis.
|
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 15.26% |
| % Held by Institutions | 14.41% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |